Search

Displaying results 3271 - 3280 of 6951 in total
  1. Drug

    ATG-Fresenius S

    go.drugbank.com/drugs/DB05320
    Investigational

    ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.

  2. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

  3. Drug

    Velusetrag

    go.drugbank.com/drugs/DB12702
    Investigational

    Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders. … It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance.

  4. Drug

    Varespladib methyl

    go.drugbank.com/drugs/DB05737
    Investigational

    Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome.

  5. Drug

    Foscarnet

    go.drugbank.com/drugs/DB00529
    ApprovedInvestigational

    An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Amyl Nitrite

    go.drugbank.com/drugs/DB01612
    Approved

    Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As...

  7. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in t...

  8. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [L50933] Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to

  9. Drug

    Lornoxicam

    go.drugbank.com/drugs/DB06725
    ApprovedInvestigational

    Lornoxicam is approved for use in Japan.

  10. Drug

    Efzofitimod

    go.drugbank.com/drugs/DB16453
    Investigational

    Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and ad...

    Categories: Experimental Unapproved Treatments for COVID-19